The impact of targeted therapy on the treatment of colorectal cancer.
In the past several years, the impact of the new biologic therapies on colorectal cancer has been dramatic. The focus of this article is to summarize some of the key advances of incorporating biologically targeted therapies into the routine management of patients with colorectal cancer. We will review important data presented at the 2005 American Society of Clinical Oncology annual meeting and discuss the incorporation of these data into the most optimal management of our patients, including how best to manage side effects and keep quality of life as high as possible.
Marshall
John L
JL
Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA. marshalj@georgetown.edu
Hwang
Jimmy
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D011788:Quality of Life
D000970:Antineoplastic Agents; D066246:ErbB Receptors